Learn

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) with rapidly evolving treatment options and strategies. The need for these guidelines was identified by the MS Interest Group of the Australian and New Zealand Association of Neurologists (ANZAN). Please refer to Part 1 for a detailed background to this article and the iterative modified Delphi process used to develop the consensus recommendations.1 The full list of recommendations is included in the Supporting Information (table 1), including the level of consensus for each recommendation and the classification using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.

This MJA Consensus Statement shares more.

Details

Authors: Jessica Shipley, James Beharry, Wei Yeh, Nabil Seery, Yi Chao Foong, Darshini Ayton, Pakeeran Siriratnam, Tracie Tan, Heidi Beadnall, Joshua Barton, Francesca Bridge, Robb Wesselingh, Lisa Taylor, Louise Rath, Jodi Haartsen, Mohammad Gadi, Cassie Nesbitt, Michael Zhong, Victoria Cushing, Fiona McKay, Julia Morahan, Benjamin Peter Trewin, Izanne Roos, Mark Marriott, Ai‐Lan Nguyen, Emma Downey, Joanne Crosby, Julian Bosco, Jennifer Taylor, Lauren Giles, Nevin John, Ernest Butler, Anneke Walt, Helmut Butzkueven, Stefan Blum, Marion Simpson, Mark Slee, Sudarshini Ramanathan, Todd Hardy, Richard A L Macdonell, Katherine Buzzard, Deborah F Mason, Jeannette Lechner‐Scott, Trevor J Kilpatrick, Tomas Kalincik, Bruce V Taylor, Simon A Broadley, Stephen Reddel, Douglas Johnson and Mastura Monif, the MS Interest Group, Australian and New Zealand Association of Neurologists

Article Type: Consensus Statement